LG Life Sciences set to commercialize new anti-hepatitis B drug in 2007

Published: 2003-12-19 07:00:00

Updated: 2003-12-19 07:00:00

LG Life Sciences announced that its own novel anti-hepatitis drug (LB80380) under development will be launched by 2007, as the drug has proven to be effective and safe as a result of foreign trials.

The company presented the clinical IIa results of LB80380 to 2003 U.S. HEP DART congress on Dec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK